The cell and gene therapy sector is poised to deliver a wave of new therapies with the potential to cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023. While manufacturing and regulatory challenges remain,…
Ferring Pharmaceuticals’ CSO on what inspires her
Ferring Pharmaceuticals Chief Scientific Officer Dr. Elizabeth Garner guides clinical development, medical affairs, pharmacovigilance, project planning and regulatory affairs. Garner has almost 30 years of experience in medicine and industry. Before joining Ferring in 2022, Garner held chief medical officer roles for biotech firm ObsEva and women’s healthcare company Agile Therapeutics. Earlier, she held leadership…